Literature DB >> 9537509

Interaction of Oct-1 and automodification domain of poly(ADP-ribose) synthetase.

J Nie1, S Sakamoto, D Song, Z Qu, K Ota, T Taniguchi.   

Abstract

We isolated several clones from a matchmaker two-hybrid system human lymphocyte cDNA library using an automodification domain of poly(ADP-ribose) synthetase (PARS) as a probe. A DNA sequence (approximately 1 kbp) of the clone was identical to part of the Oct-1 DNA sequence. We then constructed either a His-tagged or GST fusion protein of the inserted cDNA from the clone and the fusion protein was shown to interact with PARS by far-Western blot analysis and co-precipitation with affinity resin. Furthermore, the His-tagged Oct-1/POU-homeo fusion protein interacted weakly with the octamer motif of the DRa promoter and the addition of PARS fusion protein greatly increased the DNA binding activity. These results suggest that PARS interacts with Oct-1 and stabilizes the binding of Oct-1 to the octamer motif.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537509     DOI: 10.1016/s0014-5793(98)00131-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

Review 1.  Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease.

Authors:  F J Oliver; J Menissier-de Murcia; G de Murcia
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

2.  A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress.

Authors:  Jinsuk Kang; Matthew Gemberling; Mitsuhiro Nakamura; Frank G Whitby; Hiroshi Handa; William G Fairbrother; Dean Tantin
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

Review 3.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

Authors:  D D'Amours; S Desnoyers; I D'Silva; G G Poirier
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

4.  Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.

Authors:  Alberto Chiarugi
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Involvement of protein kinase Cdelta/extracellular signal-regulated kinase/poly(ADP-ribose) polymerase-1 (PARP-1) signaling pathway in histamine-induced up-regulation of histamine H1 receptor gene expression in HeLa cells.

Authors:  Hiroyuki Mizuguchi; Takuma Terao; Mika Kitai; Mitsuhiro Ikeda; Yoshiyuki Yoshimura; Asish Kumar Das; Yoshiaki Kitamura; Noriaki Takeda; Hiroyuki Fukui
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

Review 6.  PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

Authors:  Nilufer Jasmine Selimah Fauzee; Juan Pan; Ya-lan Wang
Journal:  Pathol Oncol Res       Date:  2010-04-12       Impact factor: 3.201

7.  Txk, a member of the non-receptor tyrosine kinase of the Tec family, forms a complex with poly(ADP-ribose) polymerase 1 and elongation factor 1alpha and regulates interferon-gamma gene transcription in Th1 cells.

Authors:  T Maruyama; K Nara; H Yoshikawa; N Suzuki
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

8.  Regulation of Oct1/Pou2f1 transcription activity by O-GlcNAcylation.

Authors:  Jinsuk Kang; Zuolian Shen; Jae-Min Lim; Hiroshi Handa; Lance Wells; Dean Tantin
Journal:  FASEB J       Date:  2013-04-11       Impact factor: 5.191

9.  Poly(ADP-ribose) polymerase-1 enhances transcription of the profibrotic CCN2 gene.

Authors:  Hirokazu Okada; Tsutomu Inoue; Tomohiro Kikuta; Nobutaka Kato; Yoshihiko Kanno; Narumi Hirosawa; Yasushi Sakamoto; Takeshi Sugaya; Hiromichi Suzuki
Journal:  J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 10.121

10.  Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury.

Authors:  Basilia Zingarelli; Paul W Hake; Michael O'Connor; Alvin Denenberg; Sue Kong; Bruce J Aronow
Journal:  Mol Med       Date:  2003 May-Aug       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.